Open Search
Search
中EN

Products

We are dedicated to researching and developing novel therapeutics for the treatment of cancer, autoimmune, cardiovascular diseases, and other serious unmet medical needs

  • Product Center

    QLETLI® - the first Adalimumab biosimilar in China

  • Pipeline

    Innovation for life

    • Process and Manufacture

    We have established a comprehensive quality management system in compliance with requirements applicable to and enforced by global competent authorities

    Explore Further

    Company News

    Avalon Pharma and Bio-Thera Execute Exclusive Commercialization Agreement for BAT2406, a Proposed Dupixent® Biosimilar, for MENA

    Riyadh, Saudi Arabia / Guangzhou, China – August 18, 2026 – Avalon Pharma (Middle East Pharmaceutical Industries Company), a leading Saudi-based pharmaceutical manufacturer and Bio-Thera Solutions, Lt...

    Bio-Thera Solutions Announces First Patient Dosed in Phase 1 Study for BAT8013, an Antibody Drug Conjugate Targeting CD25 for the Treatment of Advanced Solid Tumors

    Guangzhou, China --(BUSINESSWIRE)-- Bio-Thera Solutions, Ltd. (SH: 688177), a commercial-stage pharmaceutical company, today announced that dosing has begun in a Phase 1 clinical study evaluating BAT8...

    Bio-Thera Solutions’ Golimumab Biosimilars Receive FDA Approval as First Biosimilars to Simponi® and Simponi Aria®; Accord BioPharma to Commercialize IMMGOLIS™ (golimumab-sldi) and IMMGOLIS INTRI™ (golimumab-sldi) in the United States

    GUANGZHOU, China --- Bio-Thera Solutions (688177:SH), a commercial-stage biopharmaceutical company developing a pipeline of innovative therapies and biosimilars, and Accord BioPharma, Inc, the U.S. sp...

    © 2019 Bio-Thera Solutions, Ltd. All Rights Reserved. 粤ICP备17106513号